Is NSRX or NVS more undervalued in 2026?

CirclFi compares Nasus Pharma Ltd. (NSRX) and Novartis AG (NVS) using 13 institutional-grade valuation models. NSRX has a Quality of Company score of 1.9/10 while NVS scores 2.4/10.

Which is a better buy — NSRX or NVS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NSRX and NVS valuations compare?

NSRX at $3.20 and NVS at $151.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NSRX vs NVS Valuation Comparison 2026 — Intrinsic Value Analysis

NSRX

Drug Manufacturers - General

Nasus Pharma Ltd.

Quality

1.9

out of 10

Value Trap

—

Price

$3.20

Last close

Models

7/13

Active

NVS

Drug Manufacturers - General

Novartis AG

Quality

2.4

out of 10

Value Trap

—

Price

$151.40

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	NSRX Fair Value	NSRX Upside	NVS Fair Value	NVS Upside
Bayesian DCF	Intrinsic	$0.85	-73.5%	$38.01	-74.9%
Earnings Power Value	Intrinsic	—	—	$96.94	-34.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$2.27	-24.8%	$161.47	+6.9%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NSRX vs NVS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NSRX vs NVS — Which Stock Is More Undervalued?

NVS scores higher with a 2.4/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nasus Pharma Ltd. (NSRX) and Novartis AG (NVS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NSRX currently trades at $3.20 with a QOC of 1.9/10, while NVS trades at $151.40 with a QOC of 2.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).